Sensa Neuroscience

Breakthrough Therapies for Refractory Epilepsy

Sensa Neuroscience is developing a novel CBD analog that is engineered to overcome the limitations of Epidiolex in the treatment of Refractory Epilepsy, including drug interactions, liver toxicity, dosing, and bioavailability.

The PROBLEM

Epilepsy is a Complex Neurological Disorder

A significant number of epilepsy patients continue to have incompletely controlled seizures. Improved therapies that allow for better patient compliance, fewer complications with co-administered drugs, and reduced toxicities would give more patients and their providers options to safely manage their epilepsy.

~30% of patients fail to achieve seizure control with existing anti-epileptic drugs (AEDs)
Many therapies, including CBD formulations, present safety liabilities such as drug–drug interactions and liver toxicity.
Developmental and Epileptic Encephalopathies (DEEs) like Dravet and Lennox-Gastaut remain especially difficult to treat.
High variability in patient response underscores the limitations of current treatment options.

Liabilities in the available epileptic therapeutics drive the urgency for new therapies, opening the door for innovative approaches.

of epilepsy patients fail to achieve seizure control with anti-epileptic drugs (AEDs)

0 %

Higher Risk of premature mortality among people with refractory epilepsy

5- 0 x

variability in patient response to CBD highlights inconsistent outcomes

0 %

Low bioavailability limits the effectiveness of current CBD formulations like Epidiolex

0 %

global epilepsy, pain, anxiety market with significant unmet need for safer, more effective therapies

$ 0 B

OUR SOLUTION

Sensa Neuroscience: A Novel Approach and Opportunity

Sensa Neuroscience is advancing a new chemical entity designed to overcome these limitations and deliver meaningful improvements in treatment outcomes.

Our approach is the development of a CBD-derived analog that exhibits significantly improved pharmacokinetics, reduced liver accumulation, and minimized interactions with CYP3A4 and other enzymes. These enhancements create the potential for a more predictable safety profile and better tolerability for patients with refractory epilepsy, particularly those with Developmental and Epileptic Encephalopathies (DEEs).

Key Advantages of Our Approach:

Reduced adverse effects through lower liver accumulation and minimized drug–drug interactions.
Enhanced pharmacokinetics and bioavailability for more consistent therapeutic impact.
Differentiated opportunity in DEEs, a space with significant unmet medical and market needs.

EXPERTS

OUR TEAM

Sensa Neuroscience has collaborated with a highly experienced team of epilepsy and medicinal chemistry experts in the development of our drug, SEN126.

Josh Nickols, PhD

CEO

Dennis Liotta, PhD

Emory University

Stephen Traynelis, PhD

Emory University

Luke Hodson, PhD

Emory University

Jackie French, MD

NYU Langone

Dennis Dlugos, MD

CHOP

Advancing the Future of Epilepsy Care

We’re advancing breakthrough science with the potential to redefine care for patients who need more. Connect with Sensa Neuroscience to learn more about our progress, our team, and the opportunity ahead.